Research and Development in the Pharmaceutical Industry

Congressional Budget Office

No 57025, Reports from Congressional Budget Office

Abstract: CBO assesses trends in spending for prescription drug research and development (R&D) and the introduction of new prescription drugs. CBO also examines factors that determine how much drug companies spend on R&D: expected global revenues from a new drug; the cost to develop a new drug; and federal policies that affect the demand for drug therapies, the supply of new drugs, or both.

JEL-codes: H51 I11 I18 L65 O31 O38 (search for similar items in EconPapers)
Date: 2021-04-08
New Economics Papers: this item is included in nep-ind
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.cbo.gov/system/files/2021-04/57025-Rx-RnD.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cbo:report:57025

Access Statistics for this paper

More papers in Reports from Congressional Budget Office Contact information at EDIRC.
Bibliographic data for series maintained by (communications@cbo.gov).